Related Experiment Video

Updated: Apr 26, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

The future of JAK inhibition in myelofibrosis and beyond

John O Mascarenhas1, Nicholas C P Cross2, Ruben A Mesa3

  • 1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Blood Reviews
|July 22, 2014
PubMed

Insights

Targeted JAK inhibitors offer survival benefits for myeloproliferative neoplasms but do not fully resolve disease. Further research into JAK-STAT signaling is crucial for addressing unmet needs in myeloid malignancies.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Aberrant Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling drives myeloproliferative neoplasms (MPNs).
  • Ruxolitinib, a JAK1/2 inhibitor, shows efficacy and survival benefits in MPNs but has limitations.

Purpose of the Study:

  • To review the role of JAK-STAT pathway in MPN pathogenesis.
  • To discuss the efficacy and limitations of current JAK inhibitors.
  • To highlight future research directions for unmet clinical needs.

Main Methods:

  • Literature review of preclinical and clinical studies on JAK inhibitors in MPNs.
  • Analysis of data from randomized phase III trials of Ruxolitinib.
  • Discussion of ongoing clinical trials for novel JAK inhibitors and combination therapies.

Main Results:

  • Ruxolitinib improves clinical outcomes and survival in MPNs.
  • Ruxolitinib does not significantly improve cytopenias, molecular remission, or bone marrow fibrosis.
  • Novel JAK inhibitors and combination therapies are under investigation.

Conclusions:

  • JAK inhibitors represent a significant advancement in MPN treatment.
  • Addressing limitations of current therapies requires deeper understanding of MPN pathogenetic mechanisms.
  • Future strategies include novel JAK inhibitors, combination therapies, and treatment for advanced polycythemia vera.
Keywords:
JAKMyelofibrosisMyeloproliferative neoplasmsPolycythemia veraRuxolitinib

More Related Videos

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy09:17

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

6.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
56
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
99
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
125
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
72.3K